WallStreetZenWallStreetZen

NASDAQ: KRYS
Krystal Biotech Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for KRYS

Based on 8 analysts offering 12 month price targets for Krystal Biotech Inc

Min Forecast
$284.00-11.99%
Avg Forecast
$353.00+9.39%
Max Forecast
$403.00+24.89%

Should I buy or sell KRYS stock?

Based on 8 analysts offering ratings for Krystal Biotech Inc.

Strong Buy
Strong Buy
6 analysts 75%
Buy
2 analysts 25%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although KRYS's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates KRYS as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +5.11% per year. Learn More

Be the first to know when Wall Street analysts revise their KRYS stock forecasts and price targets.

KRYS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-08-04
lockedlocked$00.00+00.00%2026-07-14
lockedlocked$00.00+00.00%2026-06-18
lockedlocked$00.00+00.00%2026-06-16
lockedlocked$00.00+00.00%2026-05-05
Guggenheim
Top 13%
88
Strong BuyMaintains$284.00-12.82%2026-02-25Find out why
Chardan Capital
Top 3%
98
Strong BuyMaintains$323.00-0.85%2026-02-18Find out why
Jefferies
Top 16%
85
Strong BuyMaintains$371.00+13.88%2026-02-17Find out why

1 of 1

Forecast return on equity

Is KRYS forecast to generate an efficient return?

Company
63.71%
Industry
89.76%
Market
179%
KRYS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is KRYS forecast to generate an efficient return on assets?

Company
57.71%
Industry
39.8%
KRYS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

KRYS earnings per share forecast

What is KRYS's earnings per share in the next 3 years based on estimates from 15 analysts?

Avg 1 year Forecast
$7.63-7.78%
Avg 2 year Forecast
$9.68+17.11%
Avg 3 year Forecast
$13.66+65.19%
KRYS's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

KRYS revenue forecast

What is KRYS's revenue in the next 3 years based on estimates from 12 analysts?

Avg 1 year Forecast
$520.6M+18.19%
Avg 2 year Forecast
$671.5M+52.44%
Avg 3 year Forecast
$868.2M+97.11%
KRYS's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

KRYS earnings growth forecast

How is KRYS forecast to perform vs Biotechnology companies and vs the US market?

Company
16.98%
Industry
11.21%
Market
32.09%
KRYS's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
KRYS's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
KRYS's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

KRYS revenue growth forecast

How is KRYS forecast to perform vs Biotechnology companies and vs the US market?

Company
24.95%
Industry
30.99%
Market
13.56%
KRYS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
KRYS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

KRYS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
KRYS$325.78$353.00+8.36%Strong Buy
CYTK$78.85$106.08+34.53%Strong Buy
ABVX$125.39$154.22+22.99%Strong Buy
HALO$83.59$88.25+5.57%Strong Buy
APGE$134.23$133.19-0.78%Buy
View Top Biotech Stocks

Krystal Biotech Stock Forecast FAQ

Is Krystal Biotech Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 8 Wall Street analysts covering (NASDAQ: KRYS) stock is to Strong Buy KRYS stock.

Out of 8 analysts, 6 (75%) are recommending KRYS as a Strong Buy, 2 (25%) are recommending KRYS as a Buy, 0 (0%) are recommending KRYS as a Hold, 0 (0%) are recommending KRYS as a Sell, and 0 (0%) are recommending KRYS as a Strong Sell.

If you're new to stock investing, here's how to buy Krystal Biotech stock.

What is KRYS's earnings growth forecast for 2026-2028?

(NASDAQ: KRYS) Krystal Biotech's forecast annual earnings growth rate of 16.98% is forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.75%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.36%.

Krystal Biotech's earnings in 2026 is $241,465,000.On average, 15 Wall Street analysts forecast KRYS's earnings for 2026 to be $225,726,643, with the lowest KRYS earnings forecast at $180,132,596, and the highest KRYS earnings forecast at $270,696,155. On average, 14 Wall Street analysts forecast KRYS's earnings for 2027 to be $286,661,767, with the lowest KRYS earnings forecast at $193,185,683, and the highest KRYS earnings forecast at $379,471,877.

In 2028, KRYS is forecast to generate $404,355,618 in earnings, with the lowest earnings forecast at $221,612,405 and the highest earnings forecast at $617,224,527.

What is KRYS's revenue growth forecast for 2026-2028?

(NASDAQ: KRYS) Krystal Biotech's forecast annual revenue growth rate of 24.95% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.9%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.78%.

Krystal Biotech's revenue in 2026 is $440,484,000.On average, 12 Wall Street analysts forecast KRYS's revenue for 2026 to be $15,409,154,022, with the lowest KRYS revenue forecast at $14,010,313,032, and the highest KRYS revenue forecast at $16,443,929,328. On average, 12 Wall Street analysts forecast KRYS's revenue for 2027 to be $19,874,434,421, with the lowest KRYS revenue forecast at $15,736,221,159, and the highest KRYS revenue forecast at $22,833,726,044.

In 2028, KRYS is forecast to generate $25,698,301,392 in revenue, with the lowest revenue forecast at $19,286,601,538 and the highest revenue forecast at $33,091,498,648.

What is KRYS's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: KRYS) forecast ROA is 57.71%, which is higher than the forecast US Biotechnology industry average of 25.79%.

What is KRYS's Price Target?

According to 8 Wall Street analysts that have issued a 1 year KRYS price target, the average KRYS price target is $353.00, with the highest KRYS stock price forecast at $403.00 and the lowest KRYS stock price forecast at $284.00.

On average, Wall Street analysts predict that Krystal Biotech's share price could reach $353.00 by Aug 4, 2027. The average Krystal Biotech stock price prediction forecasts a potential upside of 8.36% from the current KRYS share price of $325.78.

What is KRYS's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: KRYS) Krystal Biotech's current Earnings Per Share (EPS) is $8.27. On average, analysts forecast that KRYS's EPS will be $7.63 for 2026, with the lowest EPS forecast at $6.09, and the highest EPS forecast at $9.15. On average, analysts forecast that KRYS's EPS will be $9.68 for 2027, with the lowest EPS forecast at $6.53, and the highest EPS forecast at $12.82. In 2028, KRYS's EPS is forecast to hit $13.66 (min: $7.49, max: $20.85).

What is KRYS's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: KRYS) forecast ROE is 63.71%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.